CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure

Pharmacogenomics Journal

Volumn 9, Issue 3, 2009, Pages 175-184

  Sharp, C F ^a   Gardiner, S J ^b   Jensen, B P ^b   Roberts, R L ^b   Troughton, R W ^a   Lainchbury, J G ^a   Begg, E J ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYTOCHROME P450 2D6; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; METOPROLOL; PAROXETINE; WARFARIN;

ALLELE; ARTICLE; BRONCHOSPASM; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; NIGHTMARE; PRIORITY JOURNAL; SYSTOLIC HEART FAILURE;

ADRENERGIC BETA-ANTAGONISTS; ALLELES; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HEART FAILURE; HUMANS; METOPROLOL; STEREOISOMERISM; SYSTOLE;

EID: 67349207939     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.9     Document Type: Article

References (37)

1. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134: 550-560.
2. Cleland JGF, Cohen-Solai A, Cosin Aguilar J, Dietz R, Eastaugh J, Follath F et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): An international survey. Lancet 2002; 360: 1631-1639.
3. Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002; 40: 491-498.
4. Lennard MS, Tucker GT, Woods HF. The polymorphic oxidation of β-adrenoceptor antagonists: Clinical pharmacokinetic considerations. Clin Pharmacokinet 1986; 11: 1-17.
5. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-397.
6. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype - major determinant of metoprolol metabolism and response. New Engl J Med 1982; 307: 1558-1560.
7. Hamelin BA, Bouayad A, Methot J, Jobin J, Desganes P, Poirier P et al Significant interaction between the nonprescription anthistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 2000; 67: 466-477.
8. Freestone S, Silas JH, Lennard MS, Ramsay LE. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. Br J Clin Pharmacol 1982; 14: 713-718.
9. Lennard MS, Silas JH, Freestone S, Trevethick J. Defective metabolism of metoprolol in poor hydroxyators of debrisoquine. Br J Clin Pharmacol 1982; 14: 301-303.
10. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12: 465-472.
11. Ismail R, Teh LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006; 31: 99-109.
12. Leemann TD, Dayer P, Meyer UA. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 1986; 29: 739-741.
13. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF. Metoprolol metabolism and debrisoquine metabolism - population and family studies. Br J Clin Pharmacol 1985; 20: 555-566.
14. Kirchheiner J. CYP2D6 phenotype prediction from genotype: Which system is the best? Clin Pharmacol Ther 2008; 83: 225-227.
15. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004; 76: 536-544.
16. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83 234-242.
17. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Gene 1997; 60: 284-295.
18. Raimundo S, Toscano C, Klein K, Fischer J, Griese E-U, Eichelbaum M et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired dunction of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 2004; 76: 128-138.
19. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS et al. adrenergic receptor polymorphisms and response during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005; 77: 127-137.
20. Fux R, Morike K, Prohmer AMT, Delabar U, Schwab M, Schaeffeler E et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study. Clin Pharmacol Ther 2005; 78: 378-387.
21. Rau T, Wuttke H, Michels LM, Werner U, Bergmann K, Kreft M et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: A prospective longitudinal study. Clin Pharmacol Ther 2009; 85 269-272.
22. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 2008; 64: 1163-1173.
23. Bijl MJ, Visser LE, van Schaik RHN, Kors JA, Witteman JCM, Hofman A et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in [beta]-blocker users. Clin Pharmacol Ther 2008; 85: 45-50.
24. Lennard MS, Tucker GT, Woods HF, Silas JH, Iyun AO. Stereoselective metabolism of metoprolol in Caucasians and Nigereans - relationship to debrisoquine oxidation phenotype. Br J Clin Pharmacol 1989; 27 613-616.
25. Seeringer A, Brockmöller J, Bauer S, Kirchheiner J. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. Eur J Clin Pharmacol 2008; 64: 883-888.
26. Clark DWJ, Morgan AKW, Waal-Manning H. Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol 1984; 18: 965-967.
27. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429-437.
28. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: Regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993; 69: 414-417.
29. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A et al. Plasma B-type natriuretic peptide levels in systolic heart failure: Importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004; 43: 416-422.
30. Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 2000; 67: 283-291.
31. Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brosen K. The oxidative metabolism of metoprolol in human liver microsomes: Inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998; 54: 261-264.
32. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet 1993; 341: 967-968.
33. Anonymous. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
34. Lainchbury JG, Troughton RW, Frampton CA, Yandle TG, Hamid A, Nicholls MG et al. NTproBNP-guided drug treatment for chronic heart failure: Design and methods in the 'battlescarred' trial. Eur J Heart Fail 2006; 8: 532-538.
35. Lahiri DK, Nurnberger Jr JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
36. Roberts RL, Kennedy MA. Rapid detection of common CYP 2D6 alleles in Caucasians. Clin Chim Acta 2006; 366: 348-351.
37. Jensen BP, Sharp CF, Gardiner SJ, Begg EJ. Development and validation of a stereoselective liquid chromatography-tandem mass spectrometry assay for quantification of S- and R-metoprolol in human plasma. J Chrom B 2008; 865: 48-54.